Novartis: combo of diabetes drugs shows long-term benefit
(CercleFinance.com) - A clinical trial for Novartis combining its Galvus drug with an older treatment resulted in a benefit for people with type 2 diabetes, according to five-year data presented on Wednesday.
The Swiss drugmaker today announced the key results from the Phase IV clinical study evaluating the long-term efficacy and safety of early combination treatment strategy with Galvus plus metformin.
The trial met the primary endpoint with a statistically significant 49% reduction in the relative risk for time to initial treatment failure versus metformin alone, Novartis said.
The study was conducted across 254 centers in 34 countries and involved 2001 treatment-naïve patients with type 2 diabetes.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The Swiss drugmaker today announced the key results from the Phase IV clinical study evaluating the long-term efficacy and safety of early combination treatment strategy with Galvus plus metformin.
The trial met the primary endpoint with a statistically significant 49% reduction in the relative risk for time to initial treatment failure versus metformin alone, Novartis said.
The study was conducted across 254 centers in 34 countries and involved 2001 treatment-naïve patients with type 2 diabetes.
Copyright (c) 2019 CercleFinance.com. All rights reserved.